Global Stereotactic Radiosurgery Market Overview:
Stereotactic radiosurgery (SRS) is a non-surgical radiation therapy that uses many precisely focused radiation beams to treat functional abnormalities and small tumors of the brain, neck, lung, liver, abdomen, and others. It can deliver precisely-targeted radiation in less high-dose treatments than traditional therapy, which can help protect healthy tissue. It is called stereotactic body radiotherapy (SBRT) when SRS is used to treat body tumors. Stereotactic radiosurgery (SRS) is an extremely precise form of radiation therapy primarily developed to treat small brain tumors and functional abnormalities of the brain.
- Growing Prevalence of Cancer and Related Diseases
- Rising Demand for Personalized Radiation Treatments
- Lack of Trained Personnel to Operate Stereotactic Radiotherapy Devices
- High Cost and Difficulty in Accessibility of Treatment
- Growing Expenditure by Governments to Prevent Cancer
- Increasing Awareness about the Importance of Radiotherapy Treatment
- Complexity Involved in Radiotherapy Techniques and Risk of Exposure of Radiation
- There Is a Slight Risk of Developing Cancer from Radiation Therapy
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are MedlinePlus (United States), The University of Texas MD Anderson Cancer Center (United States), The Johns Hopkins University (United States), Apollo Hospitals Enterprise Ltd. (India), NHS England (United Kingdom), Mayfield Brain & Spine (United States), Varian Medical Systems, Inc. (United States), Elekta (Sweden), Accuray Incorporated (United States), Uclh (United States) and Mayo Clinic (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Stereotactic Radiosurgery market by 2027. Considering Market by End-User, the sub-segment i.e. Hospitals will boost the Stereotactic Radiosurgery market. Considering Market by Equipment Used, the sub-segment i.e. Gamma Knife will boost the Stereotactic Radiosurgery market.
What Can be Explored with the Stereotactic Radiosurgery Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Stereotactic Radiosurgery Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Stereotactic Radiosurgery
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Stereotactic Radiosurgery market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Stereotactic Radiosurgery market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Brain Tumor Treatment Manufacturers, Research Professionals, Healthcare Industry, Government Body & Associations and End-User.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.